Does right ventricular dysfunction assessed by imaging or biomarkers predict mortality in patients with haemodynamically stable pulmonary embolism?
Right ventricular dysfunction, whether assessed by imaging (echocardiography/CT) or cardiac biomarkers, is significantly associated with an increased risk of mortality in patients with hemodynamically stable pulmonary embolism.
AIMS: To determine the prognostic value of right ventricular (RV) dysfunction assessed by echocardiography or spiral computed tomography (CT), or by increased levels of cardiac biomarkers troponin, brain natriuretic peptide (BNP) and pro-BNP in patients with haemodynamically stable pulmonary embolism (PE). METHODS AND RESULTS: We included all studies published between January 1985 and October 2007 estimating the relationship between echocardiography, CT or cardiac biomarkers and the risk of death in patients with haemodynamically stable PE. Twelve of 722 potentially relevant studies met inclusion criteria. The unadjusted risk ratio of RV dysfunction as assessed by echocardiography (five studies) or by CT (two studies) for predicting death was 2.4 95% confidence interval (CI) 1.3-4.4. The unadjusted risk ratio for predicting death was 9.5 (95% CI 3.2-28.6) for BNP (five studies), 5.7 (95% CI 2.2-15.1) for pro-BNP (two studies) and 8.3 (95% CI 3.6-19.3) for cardiac troponin (three studies). Threshold values differed substantially between studies for all markers. CONCLUSION: RV dysfunction assessed by CT, echocardiography, or by cardiac biomarkers are all associated with an increased risk of mortality in patients with haemodynamically stable PE. These findings should be interpreted with caution because of the clinical and methodological diversity of studies.
Sanchez et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: